Black Arrow Biotech is integrating JADBio‘s advanced AI technology into its proprietary peptide screening platform, JÜRI. This powerful combination significantly enhances Black Arrow’s high-throughput screening (HTS) capabilities, enabling more efficient and precise identification of therapeutic peptides at unprecedented speed and scale.

Within just three months of leveraging JADBio, Black Arrow has generated its first successful RNA-based therapeutic candidate. When administered, it instructs cells to produce a potent anti-cancer peptide, equipped with a targeted guidance and activation system. This novel mechanism holds promise for the treatment of multiple cancer types, marking a significant step forward in AI-driven drug development.

“The simplicity of integrating JADBio’s AI technology and the quality of its output in biomarker discovery rapidly unlocked unprecedented opportunities for us. The speed at which we can now identify and validate promising drug candidates is truly remarkable, significantly accelerating our mission to deliver cutting-edge peptide-based therapies to patients.”

Vasilis Paspaliaris, Ph.D., Black Arrow’s CEO,

“We’re very excited to see the real-world impact of our AI tools in life sciences. Black Arrow Biotech is bringing our third success in the past year where our platform delivered validated biomarkers and created new opportunities for our partners. We believe Black Arrow’s platform JÜRI, powered by our AI, has the potential to generate many breakthroughs in peptide-based drug discovery.”

Giorgos Papoutsoglou, Ph.D, JADBio’s COO

Future Directions:

HTS is a cornerstone of modern drug discovery, enabling rapid testing of thousands of compounds. For Black Arrow, peptide screening is essential to identifying bioactive sequences with therapeutic potential. By integrating JADBio’s AI technology, Black Arrow has enhanced its ability to screen and develop curated libraries of novel peptides and with greater speed, accuracy, and insight. These libraries significantly increase the likelihood of identifying successful candidates for Black Arrow, advancing its internal R&D while delivering value to pharmaceutical and biotech partners.
Building on this success, Black Arrow and JADBio will be exploring ways to scale the collaboration, making AI-powered peptide discovery more broadly accessible and impactful across the life sciences industry.

Published: Jun 17, 2025

---